Risankizumab (5) – Skyrizi®

Name: Frühe Nutzenbewertungen nach § 35a SGB V
Creator: Gemeinsamer Bundesausschuss

Moderate to severe plaque psoriasis; 6 to < 18 years

Start date	01.08.2026
Resolution	21.01.2027 – active procedure
INN	Risankizumab
Brand name	Skyrizi®
Pharm. company	AbbVie Deutschland GmbH & Co. KG
G-BA Procedure ID	D-1351
Therapeutic area	Skin diseases
Reason for procedure	New therapeutic indication

active procedures repealed resolutions


01.08.2026	21.01.2027	Risankizumab (5)	Skyrizi®	AbbVie Deutschland GmbH & Co. KG	Skin diseases	Moderate to severe plaque psoriasis; 6 to < 18 years	n.d.	active procedure
01.09.2024	20.02.2025	Risankizumab (4)	Skyrizi®	AbbVie Deutschland GmbH & Co. KG	Digestive system diseases	Ulcerative colitis, pre-treated	29,100	100% additional benefit not proven
01.01.2023	15.06.2023	Risankizumab (3)	Skyrizi®	AbbVie Deutschland GmbH & Co. KG	Digestive system diseases	Morbus Crohn, pre-treated	18,800–35,250	40% Hint for minor additional benefit
01.12.2021	19.05.2022	Risankizumab (2)	Skyrizi®	AbbVie Deutschland GmbH & Co. KG	Skin diseases	Psoriatic arthritis (PA), monotherapy or combination with methotrexate	29,100	100% additional benefit not proven
01.06.2019	22.11.2019	Risankizumab (1)	Skyrizi®	AbbVie Deutschland GmbH & Co. KG	Skin diseases	Plaque psoriasis (PP)	35,900–121,500	82% Proof of considerable additional benefit

<< List of all resolutions